Pulmonary epithelial barrier function: some new players and mechanisms

K Brune, J Frank, A Schwingshackl… - … of Physiology-Lung …, 2015 - journals.physiology.org
The pulmonary epithelium serves as a barrier to prevent access of the inspired luminal
contents to the subepithelium. In addition, the epithelium dictates the initial responses of the …

Cancer targeting with biomolecules: a comparative study of photodynamic therapy efficacy using antibody or lectin conjugated phthalocyanine-PEG gold …

G Obaid, I Chambrier, MJ Cook, DA Russell - … & Photobiological Sciences, 2015 - Springer
The functionalisation of therapeutic nanoparticle constructs with cancer-specific
biomolecules can enable selective tumour accumulation and targeted treatment. Water …

[HTML][HTML] Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer

HJ Lee, AN Seo, EJ Kim, MH Jang, YJ Kim… - British journal of …, 2015 - nature.com
Background: Epidermal growth factor receptor (EGFR) is overexpressed in a subset of
human epidermal growth factor receptor 2 (HER2)-positive breast cancers, and …

Targets for ibrutinib beyond B cell malignancies

A Berglöf, A Hamasy, S Meinke… - Scandinavian …, 2015 - Wiley Online Library
Ibrutinib (Imbruvica™) is an irreversible, potent inhibitor of Bruton's tyrosine kinase (BTK).
Over the last few years, ibrutinib has developed from a promising drug candidate to being …

Mechanisms underlying skin disorders induced by EGFR inhibitors

M Holcmann, M Sibilia - Molecular & cellular oncology, 2015 - Taylor & Francis
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is frequently
mutated or overexpressed in a large number of tumors such as carcinomas or glioblastoma …

Local variations of HER2 dimerization in breast cancer cells discovered by correlative fluorescence and liquid electron microscopy

DB Peckys, U Korf, N de Jonge - Science advances, 2015 - science.org
The formation of HER2 homodimers plays an important role in breast cancer
aggressiveness and progression; however, little is known about its localization. We have …

Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway

ST Wilks - The Breast, 2015 - Elsevier
Human epidermal growth factor receptor 2 (HER2) overexpression occurs in up to 30% of
breast cancers and is a marker of aggressive disease. While HER2-targeted therapies have …

ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity

F Belmonte, S Das, P Sysa-Shah… - American Journal …, 2015 - journals.physiology.org
Levels of the HER2/ErbB2 protein in the heart are upregulated in some women during
breast cancer therapy, and these women are at high risk for developing heart dysfunction …

Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens

D Furrer, F Sanschagrin, S Jacob… - American journal of …, 2015 - academic.oup.com
Objectives Human epidermal growth factor receptor 2 (HER2) plays a central role as a
prognostic and predictive marker in breast cancer specimens. Reliable HER2 evaluation is …

Triple negative breast cancer: a multi-omics network discovery strategy for candidate targets and driving pathways

K Karagoz, R Sinha, KY Arga - Omics: a journal of integrative …, 2015 - liebertpub.com
Triple negative breast cancer (TNBC) represents approximately 15% of breast cancers and
is characterized by lack of expression of both estrogen receptor (ER) and progesterone …